Full-Time

Vice President

Clinical Development

Confirmed live in the last 24 hours

Lyell Immunopharma

Lyell Immunopharma

201-500 employees

Develops advanced cell therapies for cancer

Biotechnology
Healthcare

Senior

Seattle, WA, USA + 1 more

More locations: San Bruno, CA, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • MD with 12 years’ experience; MD/PhD a plus; focus in oncology
  • Medically licensed, Fellowship and/or Board certification in oncology, hematology
  • A minimum of 10 years’ experience in clinical development, with substantial experience in the pharmaceutical industry leading successful clinical programs
  • Proven experience in Phase 1 clinical programs
Responsibilities
  • Develop and implement the clinical development strategy for a Program aligned with the company’s overall goals and objectives.
  • Oversee development of clinical development plans (CDPs) and clinical trial protocols.
  • Analyze and interpret clinical trial data including patient data, provide medical direction to teams for execution of protocols, to develop clinical study reports, and in making decisions and/or troubleshooting issues.
  • Oversee the monitoring and reporting of adverse events and safety signals, ensure patient safety and ethical conduct of clinical trials and develop and implement risk management strategies.
  • Ensure the scientific integrity of clinical studies and compliance with regulatory requirements.
  • Collaborate with regulatory affairs to define the regulatory strategy and provide oversight and expertise in the regulatory submission process (IND, BLA, etc.).
  • Ensure adherence to all regulatory guidelines and Good Clinical Practice (GCP) standards.
  • Lead and manage the clinical development team, provide guidance, mentorship, and professional development opportunities.
  • Represent clinical development in executive leadership meetings and contribute to strategic decision-making processes.
  • Serve as a medical representative in meetings with regulatory agencies (e.g., FDA, EMA).
  • Develop and review scientific content for regulatory documents, scientific communications and marketing materials.
  • Provide medical expertise to support product development, marketing, and sales teams.
  • Represent the company at scientific conferences, industry meetings, and in interactions with key opinion leaders (KOLs).

Lyell Immunopharma develops advanced cell therapies specifically designed to treat solid tumors, which are cancerous tissue masses. Their approach focuses on enhancing T cells, a type of immune cell, to effectively target and eliminate cancer cells. The company utilizes proprietary technologies, Gen-R and Epi-R, which involve genetic and epigenetic reprogramming of T cells to address challenges like T cell exhaustion and to ensure T cells can persist in the body. Unlike many competitors, Lyell is dedicated to creating curative treatments for solid tumors, leveraging a diverse product pipeline and a team of experts in oncology and adoptive cell therapy. Their ultimate goal is to push the limits of current cancer treatments and provide effective solutions for patients where traditional therapies have not succeeded.

Company Stage

IPO

Total Funding

$479.6M

Headquarters

San Francisco, California

Founded

2018

Growth & Insights
Headcount

6 month growth

-1%

1 year growth

-19%

2 year growth

-12%
Simplify Jobs

Simplify's Take

What believers are saying

  • Lyell's strategic partnerships, such as with MaxCyte and AWS, enhance their technological capabilities and operational efficiency.
  • The appointment of experienced leaders like Lynn Seely as CEO and Matthew Lang as Chief Business Officer strengthens the company's executive team.
  • Their state-of-the-art manufacturing facility in Bothell, Washington, supports the scalability and testing of their proprietary technologies.

What critics are saying

  • The company is still awaiting critical clinical data, which could impact investor confidence and future funding.
  • High turnover in key management positions, such as the departure of the General Counsel, may lead to strategic and operational disruptions.

What makes Lyell Immunopharma unique

  • Lyell Immunopharma focuses on T cell reprogramming to treat solid tumors, a niche area with fewer competitors compared to broader oncology treatments.
  • Their proprietary technologies, Gen-R and Epi-R, offer unique solutions to T cell exhaustion and lack of durable stemness, setting them apart from other cell therapy companies.
  • The company's commitment to scientific innovation is underscored by a world-class team of experts in oncology and adoptive cell therapy.

Help us improve and share your feedback! Did you find this helpful?